35
Views
7
CrossRef citations to date
0
Altmetric
Review

The use of modeling in the economic evaluation of vaccines

, &
Pages 443-455 | Published online: 09 Jan 2014

References

  • Trueman P, Drummond NW, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics 19 (6), 609–621 (2001).
  • Drummond ME, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcair programmes, second edition. Oxford Medical Publications, Oxford, UK (1997).
  • Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18, 3262–3282 (1999).
  • ••Excellent background article on thedifferences between static and transmission dynamic models.
  • Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? /AIWA 275, 390–397 (1996).
  • Anderson RM, May RM. Infectious diseases of humans; chnamics and control. Oxford University Press, New York, NY, USA (1991).
  • ••Textbook on the dynamics of infectiousdiseases.
  • Beutels P, Edmunds WJ, Antonanzas F et al Economic evaluation of vaccination programmes; a consensus statement focusing on viral hepatitis. PharmacoEconomics 20, 1–7(2002).
  • Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making13, 322–338 (1993).
  • Briggs A, Sculpher M. In introduction to Markov modelling for economic evaluation. PharmacoEconomics 13(4), 397–409 (1998).
  • •Excellent introduction into Markov modelling.
  • Beutels P, Bonanni P, Tormans G, Canale F, Crovari PC. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 17(19), 2400–2409 (1999).
  • Holtgrave DR (Ed.) Handbook of economic evaluation of HIV prevention programs. Plenum Press, New York, NY, USA (1998).
  • Pinkerton SD, Abrahamson PPR. Evaluating the risks: A Bernoulli proces model for HIV infection and risk reduction. Evaluation Rev 17,504–528 (1993).
  • Bos JM, Fennema JS, Postma MJ. Cost- effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS15, 2031–2036 (2001).
  • Postma MJ, Welte R, van der Hoek JAR, van Doomum GJJ, Jager JC, Coutinho RA. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis Value in I-kalth 4,266–275 (2001).
  • Rahman M, Sekimoto M, Takamatsu I etal. Economic evaluation of universal BCG vaccination of Japanese infants. Int. j Epidemiol 2,380–385 (2001).
  • Pathania VS, Trnka L, Krejbich F, Dye C. A cost-benefit analysis of BCG revaccination in the Czech Republic. Vaccine 17(15-16), 1926–1935 (1999).
  • Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluation costs and effectiveness of immunisation programmes. Epidemiol Inf. 116(1), 71–89 (1996).
  • •Example of the use of transmission dynamic models in cost-effectiveness analysis.
  • Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JA/V/A 276(14), 172–177 (1996).
  • Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JA/V/A 276(15), 1253–1258 (1996).
  • Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAIVIA 276(16), 1339–1341 (1996).
  • Gold M. Panel on cost-effectiveness in health and medicine. Merl Care 34(12 Suppl.), D5197-199 (1996).
  • Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am. Gastroenterol 97(2), 427–434 (2002).
  • Arnal JM, Frisas 0, Garuz R, Antonanzas Cost effectiveness of hepatitis A virus immunisation in Spain. PharmacoEconomics 12(3), 361–373 (1997).
  • Buma AH, Beutels P, van Damme P, Tormans G, van Doorslaer E, Leentvaar-Kuijpers A. An economic evaluation of hepatitis A vaccination in Dutch military personnel. MI Med 163(8), 564–567 (1998).
  • Fenn P, McGuire A, Gray A. An economic evaluation of vaccination against hepatitis A for frequent Travellers. j Infect. 36(1), 17–22 (1998).
  • Diel R, Rappenhohner B, Schneider S. Cost effectiveness of hepatitis A immunisation of children and adolescents in Germany. HEPA C2,96–103 (2001).
  • O'Connor JB, Imperiale TF, Singer ME. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 4,1077–1081 (1999).
  • Rajan E, Shattock AG, Fielding JF. Cost- effective analysis of hepatitis A prevention in Ireland. Am. J. Gastroenterol 95(1), 223–226 (2000).
  • Meltzer MI, Shapiro CN, Mast EE, Arcari C. The economics of vaccinating restaurant workers against hepatitis A. Vaccine 19(15-16), 2138–2145 (2001).
  • Gillis D, Yetiv N, Gdalevich M et al Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis. Vaccine 18(26), 3005–3010 (2000).
  • Jacobs RJ, Grover SF, Meyerhoff AS, Paivana TA. Cost effectiveness of vaccinating food service workers against hepatitis A infection. j Food Prot. 63(6), 768–774 (2000).
  • Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 31 (4), 834–839 (2000) .
  • Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch. Pediah: Adolesc. Merl 154(8), 763–770 (2000).
  • Saab S, Martin P, Yee HF Jr. A simple cost- decision analysis model comparing two strategies for hepatitis A vaccination. Am j Merl 109(3), 241–244 (2000).
  • Ginsber GM, Slater PE, Shouval D. Cost- benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J. Hepatol 34(1), 92–99 (2001).
  • Smith S, Weber S, Wiblin T, Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect. Control Hosp. Epidemiol 18(10), 688–691 (1997).
  • Chodick G, Lerman Y, Peled T, Aloni H, Ashkenazi S. Cost-benefit analysis of active vaccination campaigns against hepatitis A among daycare centre personnel in Israel. PhatmacoEconomics 19(3), 281–291 (2001).
  • Chodick G, Lerman Y, Wood F, Aloni H, Peled T, Ashkenazi S. Cost-utility analysis of hepatitis A prevention among healthcare workers in Israel. j Occup. Environ. Merl 44(2), 109–115 (2002).
  • Szucs T Cost-effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine 18(Suppl. 1), S86–89 (2000).
  • Wiewiora-Pilecka D. Cost-benefit analysis of the Polish hepatitis B prevention programme. Vaccine 18\(Suppl. 1), S52-54 (2000).
  • Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am. j Public Health. 88(11), 1638–1644 (1998).
  • Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. j Infect. 32(3), 197–204 (1996).
  • Garuz R, Torrea JL, Arnal JM et al Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine 15(15), 1652–1660 (1997).
  • Williams JR, Nokes DJ, Anderson RM. Targeted hepatitis B vaccination: a cost-effective immunisation strategy for the UK? Epidemiol Community Health 50,667–673 (1996).
  • Fabrizi F, Di Filippo S, Marcelli D et al Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 72(4), 536–543 (1996).
  • Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli E Intradermal versusim. hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial. 7iansplant. 12(6), 1204–1211 (1997).
  • Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. Indianj Perliatt: 67(4), 299–300 (2000).
  • Taal MW, van Zyl-Smit R. Cost- effectiveness of hepatitis B vaccination in haemodialysis patients. S. All: Merl j 91(4), 340–344 (2001).
  • Levaux HP, Schonfeld WH, Pellissier JM, Cassidy WM, Sheriff SK, Fitzsimon C. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents. Pediatrics 108(2), 317–325 (2001).
  • Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 17(13-14), 1734–1738 (1999).
  • Harris A, Yong K, Kermode M. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib—HepB): a decision analytic approach to cost effectiveness. Aust. NZJ Public Health. 25(3), 222–229 (2001).
  • Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus intluenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Atch. Perliatc Adolesc Merl 153(2), 126–136 (1999).
  • Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10), 1316–1330 (2002).
  • Tormans G, Van Doorslaer E, van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur. I Pediab: 157 (5), 395–401 (1998).
  • Iskedjian M, Einarson TR, O'Brien BJ et al Economic evaluation of a new acellular vaccine for pertussis in Canada. PhalmacoEconomics19(5 Pt 2), 551–563 (2001).
  • Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine for Coccidioides immitis Emerg. Infect. Dis. 7(5), 797–806 (2001).
  • Bos JM, Rumke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine 20 (1-2), 202–207 (2001).
  • Skull S, Butler J. Meningococcal vaccination for adolescents? An economic evaluation in Victoria. J. Paerliab: Child Health 37(5), 28–33 (2001).
  • Skull SA, Butler JR, Robinson P, Carnie J. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. int. I Epidemiol. 30(3), 571–578 (2001).
  • Parent du Chatelet I, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 19(25-26), 3420–3431 (2001).
  • Bos JM, Postma MJ. The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa. PhalmacoEconomic519(9), 937–946 (2001).
  • Sisk JE, Moskowitz AJ, Whang Wet al Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. PIMA 278(16), 1333–1339 (1997).
  • Postma MJ, Heijnen ML, Jager JC. Cost- effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. PharmacoEconomics 19(2), 215–222 (2001).
  • Baltussen RMPM, Ament AJHA, Leidl RM, van Furth R. Cost-effectiveness of vaccination against pneumococcal pneumonia in the Netherlands. Eur Public Health 7,153–161 (1997).
  • Ament A, Baltussen R, Duru G et al Cost- effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31(2), 444–450 (2000).
  • De Graeve D, Lombaert G, Goossens H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium. PharmacoEconomics 17(6), 591–601 (2000).
  • Weycker D, Richardson E, Oster G. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs. Am. J. Manag. Cate 6(10 Suppl.), S526-535 (2000).
  • Black S, Lieu TA, Ray GT, Capra A, Shinefield HR. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine 19\(Suppl. 1), S83-86 (2000).
  • Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman IF, Miller MA, Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAIVIA 283(11), 1460–1468 (2000).
  • Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin. Infect. Dis. 30(1), 157–164 (2000).
  • Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Merl 159(20), 2437–2442 (1999).
  • Hueston WJ, Mainous AG 3rd, Brauer N. Predicting cost-benefits before programs are started: looking at conjugate vaccine for invasive pneumococcal infections. J. Community Health 25(1), 23–33 (2000).
  • Marra CA, Patrick DM, Marra E A cost- effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients. Can. J. Public Health 91(5), 334–339 (2000).
  • Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J. Infect. Dis. 174\(Suppl. 3), S335-341 (1996).
  • Tennenberg AM, Brassard JE, Van Lieu J, Drusin LM. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect. Control Hasp. Epidemiol. 18(6), 405–411 (1997) .
  • Smith WJ, Jackson LA, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet. Cynecol 92(4 Pt 1), 535–545 (1998).
  • Brisson M, Edmunds WJ. The cost- effectiveness of varicella vaccination in Canada. Vaccine 20,1113–1115 (2002).
  • Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect. Control Hasp. Epidemiol. 18(7), 504–508 (1997).
  • Burnham BR, Wells TS, Riddle JR. A cost- benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. MI Med. 163(9), 631–634 (1998).
  • Gayman J. A cost-effectiveness model for analyzing two varicella vaccination strategies. Ainj Health Syst. Pharm. 55(24 Suppl. 4), 4–8 (1998).
  • Gray AM, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccination for healthcare workers. Epidemiol Infect. 119(2), 209–220 (1997).
  • Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine17(2), 142–151 (1999).
  • Howell MR, Lee T, Gaydos CA, Nang RN. The cost-effectiveness of varicella screening and vaccination in US Army recruts. Med. 165,309–315 (2000).
  • Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17(11-12), 1306–1311 (1999).
  • Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18(5-6), 407–415 (1999).
  • Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. Am. J. Med. 108(9), 723–729 (2000).
  • Olson AD, Shope TC, Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pecliab: Transplant. 5(1), 44–50 (2001).
  • Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc. Sci Med. 49(6), 763–779 (1999).
  • Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis. 33(11), 1879–1885 (2001).
  • Luce BR, Zangwill KM, Palmer CS et al Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 108(2), E24 (2001).
  • Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Economic evaluation of influenza vaccination. Assessment for The Netherlands. PharmacoEconomics16\(Suppl. 1), 33–40 (1999).
  • Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 19(30), 4204–4213 (2001).
  • Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch. Intern. Med. 161(5), 749–759 (2001).
  • Burckel E, Ashraf T, de Sousa Filho JP eta]. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. PharmacoEconomics 16(5 Pt 2), 563–576 (1999).
  • Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost-effectiveness study on influenza prevention in Hong Kong. Health Polig,56(3), 215–234 (2001).
  • Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 17\(Suppl. 3), S81-87 (1999).
  • Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 106(5), 973–976 (2000).
  • Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J. Epidemiol. Community Health 52 (2), 120–125 (1998).
  • White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 103(6), e73 (1999).
  • Bridges CB, Thompson WW Meltzer MI eta]. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAIVIA 284(13), 1655–1663 (2000).
  • Campbell DS, Rumley MET. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. I Occup. Envimn. Med. 39(5), 408–414 (1997).
  • Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J. Infect. Dis. 29(2), 181–185 (1997).
  • Limcangco MR, Armour CL, Sable EG, Taylor SJ. Cost-benefit analysis of a kkemophilus influenzae type b meningitis prevention programme in The Philippines. PharmacoEconomics 19(4), 391–400 (2001).
  • Miller MA. An assessment of the value of kkemophilus influenzae type b conjugate vaccine in Asia. Pecliab: Infect. Dis. J.17(9 Suppl.), S152-159 (1998).
  • Garpenholt 0, Silfverdal SA, Levin LA. Economic evaluation of general childhood vaccination against kkemophilus billuenzae type b in Sweden. Scand J. Infect. Dis. 30(1), 5–10 (1998).
  • Livartowski A, Boucher J, Detournay B, Reinert P. Cost-effectiveness evaluation of vaccination against kkemophilus billuenzae invasive diseases in France. Vaccine 14(6), 495–500 (1996).
  • Pokorn M, Kopac S, Neubauer D, Cizman M. Economic evaluation of kkemophilus influenzae type b vaccination in Slovenia. Vaccine 19(25-26), 3600–3605 (2001).
  • Jimenez FJ, Guallar-Castillon P, Rubio Terres C, Guallar E. Cost-benefit analysis of kkemophilus influenzae type b vaccination in children in Spain. PharmacoEconomics 15(1), 75–83 (1999).
  • Edmunds WJ, Brisson M, Rose JD. The epidemiology of Herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23-24), 3076–3090 (2001).
  • Shadick NA, Liang MET, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch. Intern. Med. 161(4), 554–561 (2001).
  • Meltzer MI, Dennis DT, Orloski IKA. The cost effectiveness of vaccinating against Lyme disease. Emerg. Infect. Dis. 5(3), 321–328 (1999).
  • Gessner BD. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly. Vaccine 18(15), 1485–1494 (2000).
  • Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 4(4), 272–280 (1999).
  • Carlin JB, Jackson T, Lane L, Bishop RF, Barnes GL. Cost effectiveness of rotavirus vaccination in Australia. Aust. NZJ Public Health 23(6), 611–616 (1999).
  • Takala AK, Koskenniemi E, Joensuu J, Makela M, Vesikari T Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin. Infect. Dir. 27(2), 272–282 (1998).
  • Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAIVIA 279(17), 1371–1376 (1998).
  • Pelletier L, Chung P, Duclos P, Manga P, Scott J. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine 16(9-10), 989–996 (1998).
  • Zwanziger J, Szilagyi PG, Kaul P Evaluating the benefits of increasing measles immunization rates. Health Set-v. Res. 36(5), 885–909 (2001).
  • Shiell A, Jorm LR, Carruthers R, Fitzsimmons GJ. Cost-effectiveness of measles outbreak intervention strategies. Aust. NZJ Public Health 22 (1), 126–132 (1998).
  • Nettleman MD, Geerdes H, Roy MC. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine. Arch. Intern. Med 157(10), 1121–1127 (1997).
  • Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen RV, Livengood JR. Economic evaluation of use of diphtheria, tetanus and acellular pertussis vaccine or diphtheria, tetanus and whole-cell pertussis vaccine in the United States, 1997. Arch. Pediatr Adolesc Med 154(8), 797–798 (2000).
  • Berdeaux G, Lafuma A, Perruchet AM, Fagnani E Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults. PhalmacoEconomics 14 (3), 313–322 (1998).
  • Graves PM. Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria Ann. Trop. Med Patasitol 92(4), 399–410 (1998).
  • Hyer RN, Howell MR, Ryan MA, Gaydos JC. Cost-effectiveness analysis of reacquiring and using adenovirus types 4 and 7 vaccines in naval recruits. Am. J. Tmp. Med Hyg 62(5), 613–618 (2000).
  • Howell MR, Nang RN, Gaydos CA, Gaydos JC. Prevention of adenoviral acute respiratory disease in Army recruits: cost-effectiveness of a military vaccination policy. Am. Bev. Med 14(3), 168–175 (1998).
  • Nancy A, Rao MR, Paquet C, Antona D, Sorkin A, Clemens JD. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAIVIA 279(7), 521–525 (1998).
  • Cookson ST, Stamboulian D, Demonte J et al A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population. Int. Epidemiol 26(1), 212–219 (1997).
  • Murray J, McFarland DA, Waldman RJ. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera. Bull. World Health Chgan. 76(4), 343–352 (1998).
  • Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. SoutheastAsianj 7i-op. Med Public Health 28(1), 143–148 (1997).
  • Warren TA, Finder SF, Brier KL eta]. A cost-effectiveness analysis of typhoid fever vaccines in US military personnel. PharmacoEconomics 10(5), 475–483 (1996).
  • Miller MA, Sutter RVV, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAIVIA 276(12), 967–971 (1996).
  • Bart KJ, Foulds J, Patriarca P. Global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Chan. 74(1), 35–45 (1996).
  • Tucker AW, Isaacs D, Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust. NZ Public Health 25(5), 411–416 (2001).
  • Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae type b and prospects for Streptococcus pneumoniae. Emerg. Inf. Dis. 5,336–345 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.